Corebridge Financial’s Summit Therapeutics SMMT Stock Holding History

Corebridge Financial’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-45,054	Closed	-$869K	–	2373
2025 Q1	$869K	Sell	45,054 -668	-1%	-$13.4K	0.01%	1322
2024 Q4	$816K	Sell	45,722 -1,087	-2%	-$21.1K	﹤0.01%	1423
2024 Q3	$1.03M	Sell	46,809 -288	-0.6%	-$4.03K	0.01%	1349
2024 Q2	$367K	Buy	+47,097	New	+$254K	﹤0.01%	1861

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Corebridge Financial's SMMT Position: Q2 2025 in Review

Corebridge Financial sold out of Summit Therapeutics (SMMT) in Q2 2025, closing a stake of 45,054 shares — an estimated $869K sold.

Corebridge Financial first reported a position in SMMT in Q2 2024 and held it in 4 quarters. The position peaked at $1.03M in Q3 2024. 238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

Corebridge Financial reported no remaining Summit Therapeutics position as of Q2 2025 after selling out during the quarter.
Corebridge Financial sold 45,054 Summit Therapeutics shares in Q2 2025, an estimated $869K.
Corebridge Financial first reported a position in Summit Therapeutics in Q2 2024 and held it in 4 quarters.
Corebridge Financial's Summit Therapeutics position peaked at $1.03M in Q3 2024.
238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.